Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19

Preexisting hypertension is a known risk factor for severe COVID-19. Abnormal activation of RAS upregulates angiotensin II (Ang-II) and contributes to severe manifestations of COVID-19. Although RAS inhibitors (RASi) are a mainstay of antihypertensive therapy, they have been associated (in some anim...

Descripción completa

Detalles Bibliográficos
Autor principal: Sackin, Henry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114589/
https://www.ncbi.nlm.nih.gov/pubmed/34048987
http://dx.doi.org/10.1016/j.mehy.2021.110609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114589/
https://www.ncbi.nlm.nih.gov/pubmed/34048987
http://dx.doi.org/10.1016/j.mehy.2021.110609

Ejemplares similares